**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 89977

**Manuscript Type:** EDITORIAL

**Can rifaximin for hepatic encephalopathy be discontinued during broad-spectrum antibiotic treatment?**

Huang CH *et al*. Rifaximin discontinuation during broad-spectrum antibiotic treatment

Chien-Hao Huang, Piero Amodio

**Chien-Hao Huang,** Division of Hepatology, Department of Gastroenterology and Hepatology, Chang-Gung Memorial Hospital, Linkou Medical Center, Taoyuan 333, Taiwan

**Piero Amodio,** Department of Clinical and Experimental Medicine, University of Padua, Padova 35122, Italy

**Author contributions:** Huang CH wrote the original manuscript; Amodio P reviewed and revised the manuscript.

**Supported by** the Chang Gung Medical Research Project, No. CMRPG3M1931-1932; the National Science and Technology Council, No. MOST 110-2314-B-182A-093- and No. NMRPG3L0331.

**Corresponding author: Piero Amodio, Doctor, MD, Academic Editor, Additional Professor,** Department of Clinical and Experimental Medicine, University of Padua, Via Giustiniani, 2, Padova 35122, Italy. piero.amodio@unipd.it

**Received:** November 19, 2023

**Revised:** January 3, 2024

**Accepted:** January 24, 2024

**Published online:** February 27, 2024

**Abstract**

Hepatic encephalopathy (HE) is a formidable complication in patients with decompensated cirrhosis, often necessitating the administration of rifaximin (RFX) for effective management. RFX, is a gut-restricted, poorly-absorbable oral rifamycin derived antibiotic that can be used in addition to lactulose for the secondary prophylaxis of HE. It has shown notable reductions in infection, hospital readmission, duration of hospital stay, and mortality. However, limited data exist about the concurrent use of RFX with broad-spectrum antibiotics, because the patients are typically excluded from studies assessing RFX efficacy in HE. A pharmacist-driven quasi-experimental pilot study was done to address this gap. They argue against the necessity of RFX in HE during broad-spectrum antibiotic treatment, particularly in critically ill patients in intensive care unit (ICU). The potential for safe RFX discontinuation without adverse effects is clearly illuminated and valuable insight into the optimization of therapeutic strategies is offered. The findings also indicate that RFX discontinuation during broad-spectrum antibiotic therapy was not associated with higher rates of delirium or coma, and this result remained robust after adjustment in multivariate analysis. Furthermore, rates of other secondary clinical and safety outcomes, including ICU mortality and 48-hour changes in vasopressor requirements, were comparable. However, since the activity of RFX is mainly confined to the modulation of gut microbiota, its potential utility in patients undergoing extensive systemic antibiotic therapy is debatable, given the overlapping antibiotic activity. Further, this suggests that the action of RFX on HE is class-specific (related to its activity on gut microbiota), rather than drug-specific. A recent double-blind randomized controlled (ARiE) trial provided further evidence-based support for RFX withdrawal in critically ill cirrhotic ICU patients receiving broad-spectrum antibiotics. Both studies prompt further discussion about optimal therapeutic strategy for patients facing the dual challenge of HE and systemic infections. Despite these compelling results, both studies have limitations. A prospective, multi-center evaluation of a larger sample, with placebo control, and comprehensive neurologic evaluation of HE is warranted. It should include an exploration of longer-term outcome and the impact of this protocol in non-critically ill liver disease patients.

**Key Words:** Rifaximin discontinuation; Hepatic encephalopathy; Broad-spectrum antibiotics; Crit-ically ill; Medical intensive care unit; Pharmacist-driven protocol

**©The** **Author(s) 2024.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Huang CH, Amodio P. Can rifaximin for hepatic encephalopathy be discontinued during broad-spectrum antibiotic treatment? *World J Hepatol* 2024; 16(2): 115-119

**URL**: <https://www.wjgnet.com/1948-5182/full/v16/i2/115.htm>

**DOI**: https://dx.doi.org/10.4254/wjh.v16.i2.115

**Core Tip:** Rifaximin (RFX) is a gut-restricted adjunct to lactulose that minimizes hepatic encephalopathy (HE) recurrence with minimal systemic absorption. Despite established benefits, limited Food and Drug Administration approval for acute HE raises concern about its use in treating acute overt HE. Recent evidence challenges the routine use of RFX with broad-spectrum antibiotics, emphasizing their class-specific effects in critically ill patients. The study sheds light on the safety of discontinuing RFX during broad-spectrum antibiotic therapy in intensive care unit patients with liver disease and HE, and also prompts reevaluation of the role of RFX amid the overlapping antibiotic activity. This evidence underscores the need for further investigations to optimize the management of both HE and systemic infections in patients with liver disease, including those who are not critically ill.

**INTRODUCTION**

Hepatic encephalopathy (HE), a neuropsychiatric complication of decompensated cirrhosis, manifests across a clinical spectrum from minimal cognitive dysfunction to lethargy and coma[1,2]. It carries substantial mortality and recurrence risks[3] and impacts the health-related quality of life in cirrhotic patients to a significant degree[4]. Despite an incomplete understanding of the comprehensive mechanisms[3], pseudo-neurotrans­mitters like gamma-aminobutyric acid (GABA), ammonia, and indole are well-established neurotoxins implicated in HE[5,6]. It has been suggested that neurotoxins, such as the ammonia produced by colonic bacteria and enterocytes that metabolize proteins, enter the systemic circulation through the portal vein and blood-brain barrier, and contribute to neurologic dysfunction and HE under cirrhotic conditions[7]. The gastrointestinal tract serves as the primary source of ammonia, with growing a recognition of gut microbiota as another significant contributor. Current drug therapies for HE, such as lactulose and rifaximin (RFX), focus on the reduction of plasma ammonia levels and the improvement of gut dysbiosis.

RFX, which has very low systemic absorption, is used as an adjunctive to lactulose to prevent the recurrence of HE[3,8]. This gut-restricted, non-absorbable rifamycin derived oral antibiotic, acts against ammonia-producing gram-positive, gram-negative, and anaerobic bacteria[9,10]. RFX demonstrates efficacy in preventing overt HE (OHE) recurrence and is linked to significant reduction in infections, hospital readmissions, and durations of hospital stay[11,12]. RFX actively improves the quality of life[13] and single-center studies suggest potential survival benefit for HE patients treated with RFX[12]. However, despite being frequently used for the prevention or treatment of acute HE[12], RFX stills awaits Food and Drug Administration approval for the treatment of acute OHE due to the limited amount of supportive evidence[14].

Antibiotics, by acting on gut microbiota, reduce indole which can potentially be converted into the neurotoxic substance oxindole in the brain[15]. They also attenuate the inflammatory response driven by pathogen-associated molecular pattern molecules (PAMPS)/endotoxins[16] and may prevent the binding of GABA in the central nervous system[17]. Notably, proinflammatory interleukins, produced during infection or an inflammatory state interact with ammonia, and can contribute to alterations in brain function[18].

In the medical intensive care unit (MICU), where infection prevalence is high[19] and infection commonly acts as a precipitant of OHE in critically ill patients[20], individuals frequently receive RFX alongside broad-spectrum antibiotics. This practice persists despite the absence of endorsement in current practice guidelines for treating OHE in the presence of infection[14]. Therefore, Ward *et al*[21] conducted a study that addressed this crucial knowledge gap; they demonstrated that RFX can be safely discontinued without adverse effect in patients with severe liver disease and HE undergoing extensive broad-spectrum antibiotic treatment in the MICU. The implicit rationale of the study suggests that the beneficial effects of RFX in HE were mainly class-specific, not drug-specific.

A plethora of antibiotic treatments has demonstrated efficacy in treating HE, with the initial recognition of tetracyclines' utility in hepatic coma[22]. Subsequent investigations highlighted the crucial role of reducing microbiota activity to reverse HE, leading to the exploration of metronidazole[23] and other poorly absorbed antibiotics like vancomycin[24], neomycin[25], and RFX[26]. These agents were preferred due to their capacity to diminish or avoid unnecessary systemic effects, considering the frequent associated systemic toxicity. Particularly noteworthy is RFX, which, among other poorly absorbed oral antibiotics, exhibits a safer profile than aminoglycosides[27]. Importantly, the development of bacterial resistance to RFX does not compromise the activity of other antibiotics[28].

Thus, the effect of antibiotics in HE is a class action[29] that is shared by the antibiotic RFX, which was found to have a profound activity on gut microbiota in the first study[30]. Later studies based on microbiome analysis found no remarkable RFX effect[31] and suggested that the effect could have been a modulation of gut microbiota metabolism. However, conclusions were driven by the analysis of the relative abundance of bacteria. Changes in the absolute microbiota burden, which is the determinant of microbiota metabolic effect, might have yielded different results. A recent elegant study by Eriksen *et al*[32] showed that RFX+ lactulose administration reduces the systemic inflow of ammonia by 20%, while the ammonia plasma level was poorly changed, thus suggesting that a single measure of fasting ammonia may be less accurate in estimating gut ammonia production in cirrhosis[32].

Considering that the mechanism of RFX action is mainly related to its positive modulation of the distorted gut microbiota profile and burden (bacterial overgrowth) in advanced cirrhosis, the possibility that its use might be useful in subjects undergoing massive systemic antibiotic use is not evident a priori, and overlapping spectra of antibiotic activity with broad-spectrum antibiotics are expected.

The Ward *et al*[21] study has several limitations. As a single-center study, its generalizability may be limited, and variations in patient populations across centers may impact external validity. Second, the retrospective data collection introduces inherent limitations, including incomplete or missing data, recall bias, and an inability to control for all confounding variables. Third, despite including both acute and chronic HE, the absence of subgroup analysis may limit result interpretation. Fourth, reliance on surrogate endpoints such as days alive and freedom from delirium and coma, instead of West-Haven grades, may introduce variability and might not fully capture the impact, especially in assessing acute HE episodes. Fifth, the study did not assess long-term outcomes or the sustained effects of withheld RFX therapy, which could underestimate the beneficial role of RFX. Sixth, despite generally balanced groups, observed baseline differences, such as norepinephrine requirements and race, may potentially confound results. Seventh, the study enrolled critically ill patients with liver disease, representing a spectrum from compensated cirrhosis to decompensated liver cirrhosis without analyzing their Model for end stage liver disease scores, which greatly impact prognoses.

**CONCLUSION**

At any rate, data supporting the combination use of RFX with broad-spectrum antibiotics are limited, as patients on broad-spectrum antibiotics have generally been excluded from studies on RFX efficacy in HE. Therefore, the Ward *et al*[21] study has great merit, since it provides an evidence-based argument to justify RFX withdrawal in patients with cirrhosis who receive broad-spectrum antibiotic treatment. Further, this is in agreement with the recent article by Kulkarni *et al*[14], which does not show any advantage on HE in patients with or without RFX that are treated with other antibiotics. Thus, both articles provide empirical evidence as to what could have been assumed only *a priori* based on antibiotic action. Despite these compelling results, it is crucial to acknowledge limitations in these studies. A prospective, multi-center evaluation in a larger sample, with placebo control and comprehensive neurologic evaluations for HE, might be useful. Additionally, exploring the impact of this protocol in non-critically ill liver disease patients should be considered.

**REFERENCES**

1 **Vilstrup H**, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. *Hepatology* 2014; **60**: 715-735 [PMID: 25042402 DOI: 10.1002/hep.27210]

2 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. *J Hepatol* 2022; **77**: 807-824 [PMID: 35724930 DOI: 10.1016/j.jhep.2022.06.001]

3 **Wijdicks EF**. Hepatic Encephalopathy. *N Engl J Med* 2016; **375**: 1660-1670 [PMID: 27783916 DOI: 10.1056/NEJMra1600561]

4 **Montagnese S**, Bajaj JS. Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues. *Drugs* 2019; **79**: 11-16 [PMID: 30706419 DOI: 10.1007/s40265-018-1019-y]

5 **Aldridge DR**, Tranah EJ, Shawcross DL. Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. *J Clin Exp Hepatol* 2015; **5**: S7-S20 [PMID: 26041962 DOI: 10.1016/j.jceh.2014.06.004]

6 **Moroni F**, Carpenedo R, Venturini I, Baraldi M, Zeneroli ML. Oxindole in pathogenesis of hepatic encephalopathy. *Lancet* 1998; **351**: 1861 [PMID: 9652676 DOI: 10.1016/S0140-6736(05)78807-3]

7 **Hadjihambi A**, Arias N, Sheikh M, Jalan R. Hepatic encephalopathy: a critical current review. *Hepatol Int* 2018; **12**: 135-147 [PMID: 28770516 DOI: 10.1007/s12072-017-9812-3]

8 **Häussinger D**, Dhiman RK, Felipo V, Görg B, Jalan R, Kircheis G, Merli M, Montagnese S, Romero-Gomez M, Schnitzler A, Taylor-Robinson SD, Vilstrup H. Hepatic encephalopathy. *Nat Rev Dis Primers* 2022; **8**: 43 [PMID: 35739133 DOI: 10.1038/s41572-022-00366-6]

9 **Adachi JA**, DuPont HL. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. *Clin Infect Dis* 2006; **42**: 541-547 [PMID: 16421799 DOI: 10.1086/499950]

10 **Calanni F**, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: beyond the traditional antibiotic activity. *J Antibiot (Tokyo)* 2014; **67**: 667-670 [PMID: 25095806 DOI: 10.1038/ja.2014.106]

11 **Salehi S**, Tranah TH, Lim S, Heaton N, Heneghan M, Aluvihare V, Patel VC, Shawcross DL. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list. *Aliment Pharmacol Ther* 2019; **50**: 435-441 [PMID: 31169941 DOI: 10.1111/apt.15326]

12 **Kimer N**, Krag A, Møller S, Bendtsen F, Gluud LL. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. *Aliment Pharmacol Ther* 2014; **40**: 123-132 [PMID: 24849268 DOI: 10.1111/apt.12803]

13 **Bakulin IG**, Ivanova KN, Eremina EY, Marchenko NV; NORMIND study team. Comparative Analysis of the Efficacy of Different Regimens of 12 Months Rifaximin-Alfa Therapy in Patients with Liver Cirrhosis and Minimal Hepatic Encephalopathy. *Diagnostics (Basel)* 2023; **13** [PMID: 37892060 DOI: 10.3390/diagnostics13203239]

14 **Kulkarni AV**, Avadhanam M, Karandikar P, Rakam K, Gupta A, Simhadri V, Premkumar M, Zuberi AA, Gujjarlapudi D, Narendran R, Shaik S, Sharma M, Iyengar S, Alla M, Venishetty S, Reddy DN, Rao PN. Antibiotics With or Without Rifaximin for Acute Hepatic Encephalopathy in Critically Ill Patients With Cirrhosis: A Double-Blind, Randomized Controlled (ARiE) Trial. *Am J Gastroenterol* 2024 [PMID: 37942950 DOI: 10.14309/ajg.0000000000002575]

15 **Carpenedo R**, Mannaioni G, Moroni F. Oxindole, a sedative tryptophan metabolite, accumulates in blood and brain of rats with acute hepatic failure. *J Neurochem* 1998; **70**: 1998-2003 [PMID: 9572285 DOI: 10.1046/j.1471-4159.1998.70051998.x]

16 **Bernardi M**, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. *J Hepatol* 2015; **63**: 1272-1284 [PMID: 26192220 DOI: 10.1016/j.jhep.2015.07.004]

17 **Smolders I**, Gousseau C, Marchand S, Couet W, Ebinger G, Michotte Y. Convulsant and subconvulsant doses of norfloxacin in the presence and absence of biphenylacetic acid alter extracellular hippocampal glutamate but not gamma-aminobutyric acid levels in conscious rats. *Antimicrob Agents Chemother* 2002; **46**: 471-477 [PMID: 11796360 DOI: 10.1128/AAC.46.2.471-477.2002]

18 **Shawcross DL**, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. *J Hepatol* 2004; **40**: 247-254 [PMID: 14739095 DOI: 10.1016/j.jhep.2003.10.016]

19 **Vincent JL**, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, Finfer S, Pelosi P, Brazzi L, Aditianingsih D, Timsit JF, Du B, Wittebole X, Máca J, Kannan S, Gorordo-Delsol LA, De Waele JJ, Mehta Y, Bonten MJM, Khanna AK, Kollef M, Human M, Angus DC; EPIC III Investigators. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. *JAMA* 2020; **323**: 1478-1487 [PMID: 32207816 DOI: 10.1001/jama.2020.2717]

20 **Shawcross DL**, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, Auzinger G, Bernal W, Wendon JA. Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. *J Hepatol* 2011; **54**: 640-649 [PMID: 21163546 DOI: 10.1016/j.jhep.2010.07.045]

21 **Ward JA**, Yerke J, Lumpkin M, Kapoor A, Lindenmeyer CC, Bass S. Evaluation of a protocol for rifaximin discontinuation in critically ill patients with liver disease receiving broad-spectrum antibiotic therapy. *World J Hepatol* 2023; **15**: 1226-1236 [PMID: 38075005 DOI: 10.4254/wjh.v15.i11.1226]

22 **Dawson AM**, Sherlock S, Summerskill WH. The treatment and prognosis of hepatic coma. *Lancet* 1956; **271**: 689-694 [PMID: 13368499 DOI: 10.1016/S0140-6736(56)92383-2]

23 **Morgan MH**, Read AE, Speller DC. Treatment of hepatic encephalopathy with metronidazole. *Gut* 1982; **23**: 1-7 [PMID: 7035298 DOI: 10.1136/gut.23.1.1]

24 **Tarao K**, Ikeda T, Hayashi K, Sakurai A, Okada T, Ito T, Karube H, Nomoto T, Mizuno T, Shindo K. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. *Gut* 1990; **31**: 702-706 [PMID: 2199349 DOI: 10.1136/gut.31.6.702]

25 **Summerskill WH**. Hepatic coma in liver failure and gastro-intestinal haemorrhage treated with neomycin. *Br Med J* 1958; **2**: 1322-1325 [PMID: 13596598 DOI: 10.1136/bmj.2.5108.1322]

26 **Bass NM**, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. *N Engl J Med* 2010; **362**: 1071-1081 [PMID: 20335583 DOI: 10.1056/NEJMoa0907893]

27 **Mullen KD**, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. *Clin Gastroenterol Hepatol* 2014; **12**: 1390-7.e2 [PMID: 24365449 DOI: 10.1016/j.cgh.2013.12.021]

28 **Scarpignato C**, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. *Chemotherapy* 2005; **51**: 36-66 [PMID: 15855748 DOI: 10.1159/000081990]

29 Antibiotics in hepatic coma. *Br Med J* 1958; **1**: 512 [PMID: 13510715]

30 **Testa R**, Eftimiadi C, Sukkar GS, De Leo C, Rovida S, Schito GC, Celle G. A non-absorbable rifamycin for treatment of hepatic encephalopathy. *Drugs Exp Clin Res* 1985; **11**: 387-392 [PMID: 3836135]

31 **Kang DJ**, Kakiyama G, Betrapally NS, Herzog J, Nittono H, Hylemon PB, Zhou H, Carroll I, Yang J, Gillevet PM, Jiao C, Takei H, Pandak WM, Iida T, Heuman DM, Fan S, Fiehn O, Kurosawa T, Sikaroodi M, Sartor RB, Bajaj JS. Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition. *Clin Transl Gastroenterol* 2016; **7**: e187 [PMID: 27560928 DOI: 10.1038/ctg.2016.44]

32 **Eriksen PL**, Djernes L, Vilstrup H, Ott P. Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia-targeting treatments. *J Hepatol* 2023; **79**: 340-348 [PMID: 37061198 DOI: 10.1016/j.jhep.2023.03.042]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** November 19, 2023

**First decision:** December 8, 2023

**Article in press:** January 24, 2024

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Taiwan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Perazzo JC, Argentina **S-Editor:** Li L **L-Editor:** A **P-Editor:** Li L



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** office@baishideng.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2024 Baishideng Publishing Group Inc. All rights reserved.**